Like breakthrough news of natural catastrophe, a radically different concept regarding the pathogenesis of multiple sclerosis (MS) has been proposed omitting the previous decades of research work in that field . Termed chronic cerebrospinal venous insufficiency (CCSVI), it suggests that macro occlusive abnormalities of the extracranial venous drainage pathways of the brain and spinal cord can cause or /and contribute to MS. Consequently, it has been suggested that angioplasty and possibly stenting of the internal jugular and/or azygos veins can improve the signs and symptoms of MS (Zamboni 2006; Zamboni, Menegatti et al. 2007) . Since this breakthrough news a fierce pandemic has striked worldwide where these endovascular interventions have been performed sporadically across the globe in an open label fashion and never in the context of a well designed, controlled, randomized and blinded clinical trial. Despite this, this procedure 'liberation procedure' as it has been labeled by some ; sparkled a firestorm of interest in the medical and neurological communities, in both directions , to perform and not to perform. Each team has their rationale which is passionate at best, ranging from the myth that venous intervention is a miracle cure that must not be withheld from patients, to the feeling that the procedure is ineffective, unwarranted and dangerous at worst. The various views commonly see that those with differing beliefs are not acting in the best interest of the patients. As MS is a tuft practice of neurology, and neurointerventionalists interested in interventional treatment of neurological disorders are the neurology `s delivery man for neurointerventional procedures, we will attempt to analyze the available data and provide accordingly recommendations about whether or not endovascular treatment represents a reasonable option at this point of time for MS patients . To imagine the magnitude of a natural catastrophe, you should firstly bypass the denial phase to start counting the losses. So we will examine the source of the CCSVI theory and discuss the current data calling for or refuting its existence.
INTRODUCTION
Like breakthrough news of natural catastrophe, a radically different concept regarding the pathogenesis of multiple sclerosis (MS) has been proposed omitting the previous decades of research work in that field . Termed chronic cerebrospinal venous insufficiency (CCSVI), it suggests that macro occlusive abnormalities of the extracranial venous drainage pathways of the brain and spinal cord can cause or /and contribute to MS. Consequently, it has been suggested that angioplasty and possibly stenting of the internal jugular and/or azygos veins can improve the signs and symptoms of MS (Zamboni 2006; Zamboni, Menegatti et al. 2007 ).
Since this breakthrough news a fierce pandemic has striked worldwide where these endovascular interventions have been performed sporadically across the globe in an open label fashion and never in the context of a well designed, controlled, randomized and blinded clinical trial. Despite this, this procedure 'liberation procedure' as it has been labeled by some ; sparkled a firestorm of interest in the medical and neurological communities, in both directions , to perform and not to perform.
Each team has their rationale which is passionate at best, ranging from the myth that venous intervention is a miracle cure that must not be withheld from patients, to the feeling that the procedure is ineffective, unwarranted and dangerous at worst.
The various views commonly see that those with differing beliefs are not acting in the best interest of the patients. As MS is a tuft practice of neurology, and neurointerventionalists interested in interventional treatment of neurological disorders are the neurology `s delivery man for neurointerventional procedures, we will attempt to analyze the available data and provide accordingly recommendations about whether or not endovascular treatment represents a reasonable option at this point of time for MS patients . To imagine the magnitude of a natural catastrophe, you should firstly bypass the denial phase to start counting the losses. So we will examine the source of the CCSVI theory and discuss the current data calling for or refuting its existence.
BRIEF REVIEW OF MULTIPLE SCLEROSIS
MS is a nightmare for both patient and practicing neurologist. It is an unpredictable disease that brings an enormous physical, emotional and financial burden on patients, family, relatives, friends and society in general. It is the most common cause of physical disability, where prevalence of MS differs widely worldwide. In Caucasians, MS occurs in about 40 to 100 a person in 100,000, whereas in most East Asians and South Asians it is less than 10 in 100,000, and among Africans it is even fewer.(http://www.ninds.nih.gov/disorders/multiple_sclerosi s/detail_multiple_sclerosis.htm) Such big differences seem to suggest that different genetic backgrounds among races strongly affect MS susceptibility.
In temperate zones, a south-to-north gradient of MS prevalence has been shown repeatedly. This tendency is seen in high prevalence areas such as the United States, Europe, and Australia, as well as in low prevalence areas such as Japan.
The peak age at onset is 20-40 years. It affects females more than males and is more common among Caucasians. MS can present with just about any neurological symptom in any part of the nervous system, cranial nerves , visual , motor , coordination, sensory , autonomic, and myelopathic on different occasions with progressive disability.1 Diagnosis is based on clinico-radiological criteria (McDonald criteria) to establish the dissemination in place (different CNS sites) and time (at least 30 days between clinical relapses and 90 days for new MRI lesion without clinical relapse).
The clinical course of MS is most commonly relapsing remitting, with return to baseline after each relapse, followed by secondary progressive starting as relapsing remitting, then primary progressive MS. (Compston and Coles 2008) The most prevalent hypothesis regarding the pathophysiological basis for MS is that it is an autoimmune inflammatory disease triggered by Environmental factors and genetic predisposition ; the former related to latitude, shortage of sunlight, low temperatures, or even certain infectious pathogens more frequent in northern areas are suspected. For example, less ultraviolet light during the winter in northern areas causes lower vitamin D3 production. Vitamin D possesses an immunoregulatory function and suppresses the development of experimental autoimmune encephalomyelitis in laboratory animals. (Compston and Coles 2008) Thus, the lower production of vitamin D might partly explain the south-tonorth gradient of MS risk.
On the other hand, the genetic predisposition leading to myelin and axonal destruction in the brain and spinal cord by the immune system; the hypothesis that got consolidation from studies in Canada that revealed that MS risk was 300 times higher in twins, and the concordance rate of MS in monozygotic twins is significantly higher than in dizygotic twins(about 30% versus 5%), indicating the importance of genetic background. 
TO BE KEPT IN MIND WHEN READING IN BETWEEN LINES
Pretreatment pressures beyond the stenosis were not significantly different from normal venous pressure and there was no significant change in pressure after angioplasty. Mean follow-up using extracranial Doppler was 18 months, with an overall restenosis rate of 47%; more common in the jugular than azygos veins. Clinical outcome at 18 months was reported as showing relapse free of 50%versus 27% preoperatively ). It is important to note that the interpretation of the clinical results of this uncontrolled study is confounded since patients were continued on 'immunemodulating' therapy after endovascular therapy. 
CCSVI CONCEPT AND ITS RELATION TO MS , DECEIVING RELATIONSHIP AT WORST OR CO-MORBID RELATIONSHIP AT BEST OF CHANCES (NO THERAPEUTIC INDICATOR NOR RESPONSE BENCHMARK)
This concept should be carefully interpreted in relation to MS pathology, whether it is causal or comorbid relationship , this should be kept in mind specially in the light of the following facts .
A-ANATOMICAL PHYSIOLOGICAL ENIGMA
To explain this enigma, one must understand the hemodynamics of cerebral venous outflow. The brain has two methods of venous drainage: blood drains anteriorly through the internal jugular system in the supine position and posteriorly through the vertebral system when erect. Normally, in the upright position, the jugular vein collapses (narrows) because there is not enough blood flow through it to maintain distension. In the supine position, the normal IJVs distend because the supine position favors jugular flow (IJV drainer) which represent 70% of cases.
The same issues apply when there is increased resistance to jugular flow. The alternate vertebral venous outflow system shunts blood away from the jugular veins (non-IJV drainer) which represent 30% of cases. Because pressure is normally low and only marginally rises with obstruction, distension of the obstructed system does not occur. 
B-SELECTING NON LOCALIZING MS MANIFESTATION FOR EVALUATING THERAPEUTIC RESPONSE
Some of the symptoms of MS mimic those observed in patients with superior vena cava syndrome. Relief of superior vena cava obstruction with venous angioplasty and stent placement, if required, provides swift and dramatic resolution of the symptoms of impaired cognition and fatigue. (Philips, Bagley et al. 1999 ) Thus, it is not surprising that patients with CCSVI associated with MS also report rapid relief of this non-localizing symptoms. It is wellrecognized; however, that many symptoms of MS fluctuate and are largely subjective. It is possible that in the initial nonrandomized patient series reported to date, the improvement in symptoms could reflect a strong placebo effect. This is why we suggest to investigate this diagnostic constellation of manifestations in frame of relating the CCSVI to chronic fatigue syndrome which is highly comorbid with MS patients.
Nonetheless, the biological plausibility linking cerebral venous congestion to inflammation that is the hallmark of MS requires serious consideration. Whether the relief of the venous obstruction will have an impact on the course of the neurological disease remains to be seen.
Although the initial observations relating CCSVI and MS are interesting and potentially paradigm-shifting, they now need rigorous testing. (Zamboni 2006 ) On the other hand, there are life-threatening adverse effects that may complicate endovascular management of CCSVI. A randomized clinical trial is needed to assess the risks and benefits of endovascular treatment of this condition.
C-IN THE ABSENCE OF RCTS, PRACTICING ENDOVASCULAR VENOUS INTERVENTIONS FOR MS PATIENTS IS LIKE RATIONALIZING PARAPSYCHOLOGY PRACTICE TO REPLACE MEDICINE
It can only be hoped that the future will not judge us as irresponsible when we choose not to evaluate established procedures in the same way, on the (in my opinion undefensible) grounds that it is 'unethical'.
There are many physicians and others who have endovascular skills who are promoting and developing centers for serving these patients without regard for the lack of scientific evidence to support such practice. Patients with this disease have frequently suffered for long periods of time, often without great relief of symptoms and are often desperate for any alternative that may offer hope. Consequently, we should remain very concerned about the possibility of misleading these individuals or exposing them to additional risk, outside of scientific efforts to get a better understanding of this potentially exciting therapy.
Given the concerns of the neurology community, it would be unfortunate if the attempts to advance this field suffer the consequences of premature promotion of a procedure that could mislead patients, sponsors, and regulators. So, a global initiative to meticulously document the prevalence of venous anomalies in MS, by comparison to age and gender-matched healthy individuals, as well as those with neurological disease not due to MS is more warranted.
In part, recent grants from the National MS Society awarded to seven investigative groups to study CCSVI will help initiate this effort in the United States and Canada. (NIH Jun 11, 2010) These observations may provide a basis for clinical trial in MS to assess the long-term safety and efficacy of endovascular procedures in restoring normal venous hemodynamics, in relieving the non localizing symptoms secondary to venous obstruction, and in slowing or halting the inflammatory and demyelinating processes. In parallel, the development of animal models will advance our understanding of how CCSVI may influence or even initiate the pathophysiology of MS.
CHALLENGES TO THE ZAMBONI THESIS CREDIBILITY (WHAT IS AGAINST CCSVI ROLE IN MS)
Although the Zamboni papers have been quite supportive of CCSVI, there is a growing number of papers that raise serious questions about its validity. In early 2010, Khan et al described a number of independently accepted characteristics of venous disease and MS that contradict the CCSVI theory: (Khan, Filippi et al. 2010) Similar to other autoimmune diseases, MS is more 1.
common in young women while chronic venous insufficiency syndromes are not.
There are well known strong epidemiological 2.
associations between MS and environmental factors and genetic factors as above mentioned that are not mirrored by chronic venous insufficiency.
Central veno-occlusive disease can lead to 3.
syndromes of idiopathic intracranial hypertension, ischemic and hemorrhagic infarcts and edema, none of which is typically seen in MS patients.
Vascular abnormalities related to chronically 4.
diminished venous flow would be expected to increase over time, yet after the age of 50 years the incidence of MS is quite low.
There is no other model of decreased venous 5.
drainage and an organ specific immune response.
Transient global ischemia is known to occur with 6. jugular insufficiency but this entity is not seen in MS.
Radical neck dissections remove all jugular veins 7.
but they have never been seen to cause MS.
The above cited challenges to the Zamboni thesis are based on largely theoretical considerations. In an attempt to replicate the Doppler findings of Zamboni, Doepp et al studied 56 MS patients and 20 controls using similar CCSVI criteria. (Doepp, Paul et al. 2010 ) They found no patients in either the MS or control groups who had the two or more criteria required for a diagnosis of CCSVI. They concluded, based on these results as well as their extensive longitudinal experience with cranial venous Doppler ultrasound, that there is typically tremendous reserve capacity of the extrajugular pathways for cerebral venous drainage and that it is highly unlikely that IVJ stenosis would cause central venous congestion. Furthermore, they went on to discourage interventional procedures for CCSVI outside of the context of appropriately designed clinical research studies. 
SUMMARY
There is little debate as to the potential ravages of MS and the sincere need to improve outcomes in patients suffering from this horrible disease. As such, when seemingly miraculous cures are proffered, it is our responsibility as Neuroscience communities to rationally review its benefit . There are few data supporting the validity of CCSVI. The lack of data could be counterbalanced by the great hope for the miracle of an endovascular treatment for such terrible disease. The topic has caused widespread attention and debate in the media, medical literature and the internet. (Hojnacki, Zamboni et al. 2010; Zivadinov, Schirda et al. 2010) As of late October 2010, a Google search on 'liberation procedure' yielded about 3,650,000 results and approximately 189,000 for 'CCSVI'. Sponsored links appear for treatment in many places around earth e.g. Costa Rica, India ,Mexico, Poland, Egypt and many other locations. The prospect of opening an open label, non-study related MS endovascular CCSVI practice can be very seductive from both physician and patient sides. For physicians, the barriers to entry are small since most interventionalists are technically able to perform these procedures and the required devices are readily available. At the same time, there are many patients who are desperate for a procedure which might improve their condition despite the lack of evidence to support its benefits and almost regardless of its potential risks. Some might argue that "the procedure is safe, if there is any possibility of ameliorating some of the symptoms of MS patients the procedure should not withheld from them". However, no invasive procedure is completely safe. In fact, there are increasing reports of complications related to PTA or stenting for CCSVI, including intracranial hemorrhage, stent migration into the heart and jugular vein thrombosis . Many patients are willing to pay cash, sometimes tens of thousands of dollars, for a single procedure. Many patients rave about their procedures, yet outside of a well controlled trial, it is hard to disprove the placebo effect and prove the true clinical benefits. In view of the forgoing, and in an attempt to help resolve the CCSVI conundrum, it would seem that the fundamental questions are:
Is that a cause relationship , if any or just 1.
comorbdity between CCSVI and MS, and in which direction does this work? 
HOW WE COULD MEDICALLY INVEST CCSVI
Until we have clear evidence regarding such phenomenon and its association with MS and its treatment safety and efficacy, I prefer its discussion as an observational phenomenon not a pathophysiological one. Consequently, more evidence is needed to establish the association between CCSVI and MS. If more solid clinical evidence can confirm that the CCSVI-MS relationship is real, randomized clinical trials will be required to assess the benefits of endovascular interventions. If these trials establish a benefit for endovascular therapy, then at that point treatment can be made widely available. However, until these steps are taken, in our opinion, there is no role for the endovascular treatment of CCSVI in the MS patient outside of approved clinical trials.
